{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:15:22Z","timestamp":1773872122129,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003762","name":"Institut Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["LA\/P\/0140\/2020"],"award-info":[{"award-number":["LA\/P\/0140\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["CPCA.A2"],"award-info":[{"award-number":["CPCA.A2"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04378\/2020"],"award-info":[{"award-number":["UIDB\/04378\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2023.10437"],"award-info":[{"award-number":["2023.10437"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDP\/04378\/2020"],"award-info":[{"award-number":["UIDP\/04378\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015510","name":"Infrastructures en Biologie Sant\u00e9 et Agronomie","doi-asserted-by":"publisher","award":["ANR-20-CO10-0001-01"],"award-info":[{"award-number":["ANR-20-CO10-0001-01"]}],"id":[{"id":"10.13039\/100015510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006489","name":"Commissariat \u00e0 l&apos;\u00c9nergie Atomique et aux \u00c9nergies Alternatives","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006489","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007277","name":"Icahn School of Medicine at Mount Sinai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007277","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013414","name":"Conseil R\u00e9gional des Pays de la Loire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009371","name":"Universit\u00e9 de Nantes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009371","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018429","name":"Istituto Europeo di Oncologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ijbiomac.2025.149321","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:47:03Z","timestamp":1764290823000},"page":"149321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Optimized pipeline for generating highly potent neutralizing Affitins: Application to SARS-CoV-2 spike protein"],"prefix":"10.1016","volume":"336","author":[{"given":"Thomas","family":"Maurice","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lanie","family":"Laporte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Barquilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s","family":"Fortun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klara","family":"Echasserieau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Guivel-Benhassine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arm\u00e9nio Jorge","family":"Moura Barbosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Cossard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyril","family":"Planchais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Anna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Charneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Mouquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Cec\u00edlia","family":"Afonso Roque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Mouratou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Davodeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine","family":"Bernardeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blandine","family":"Monel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Pecorari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2025.149321_bb0005","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ijbiomac.2021.01.076","article-title":"Trends and strategies to combat viral infections: a review on FDA approved antiviral drugs","volume":"172","author":"Tompa","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0010","first-page":"CD013757","article-title":"Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children","volume":"11","author":"Garegnani","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0015","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1177\/1060028020942218","article-title":"Ibalizumab: the first monoclonal antibody for the treatment of HIV-1 infection","volume":"55","author":"Chahine","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.105902","article-title":"New technologies in therapeutic antibody development: the next frontier for treating infectious diseases","volume":"227","author":"Keating","year":"2024","journal-title":"Antiviral Res."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.721328","article-title":"Review: insights on current FDA-approved monoclonal antibodies against Ebola virus infection","volume":"12","author":"Tshiani Mbaya","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0030","article-title":"Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies","volume":"3","author":"Bruel","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0035","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2221247120","article-title":"Complement contributes to antibody-mediated protection against repeated SHIV challenge","volume":"120","author":"Goldberg","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0040","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01743-21","article-title":"Revisiting an IgG Fc loss-of-function experiment: the role of complement in HIV broadly neutralizing antibody b12 activity","volume":"12","author":"Goldberg","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0045","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/pro.3319","article-title":"The bulky and the sweet: how neutralizing antibodies and glycan receptors compete for virus binding","volume":"26","author":"Dietrich","year":"2017","journal-title":"Protein Sci."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0050","doi-asserted-by":"crossref","first-page":"7385","DOI":"10.1073\/pnas.0811427106","article-title":"Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10","volume":"106","author":"Klein","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0055","doi-asserted-by":"crossref","first-page":"878","DOI":"10.2174\/1389201021999200824101035","article-title":"Recent advances in the scaffold engineering of protein binders","volume":"22","author":"Ahmadi","year":"2021","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0060","doi-asserted-by":"crossref","DOI":"10.1038\/srep37274","article-title":"The archaeal \u201c7\u00a0kDa DNA-binding\u201d proteins: extended characterization of an old gifted family","volume":"6","author":"Kalichuk","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097438","article-title":"Potent and specific inhibition of glycosidases by small artificial binding proteins (Affitins)","volume":"9","author":"Correa","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0070","doi-asserted-by":"crossref","first-page":"17983","DOI":"10.1073\/pnas.0702963104","article-title":"Remodeling a DNA-binding protein as a specific in vivo inhibitor of bacterial secretin PulD","volume":"104","author":"Mouratou","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0075","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/protein\/gzs106","article-title":"Tolerance of the archaeal Sac7d scaffold protein to alternative library designs: characterization of anti-immunoglobulin G Affitins","volume":"26","author":"B\u00e9har","year":"2013","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0080","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/bit.26989","article-title":"Whole-bacterium ribosome display selection for isolation of highly specific anti-Staphylococcus aureus Affitins for detection- and capture-based biomedical applications","volume":"116","author":"Behar","year":"2019","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0085","doi-asserted-by":"crossref","DOI":"10.1021\/acsami.9b05702","article-title":"Multivalent affidendrons with high affinity and specificity towards Staphylococcus aureus as versatile tools for modulating multicellular behaviors","author":"Vukojicic","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0090","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.chroma.2016.02.068","article-title":"Affitins as robust tailored reagents for affinity chromatography purification of antibodies and non-immunoglobulin proteins","volume":"1441","author":"B\u00e9har","year":"2016","journal-title":"J. Chromatogr."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0095","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1016\/S1473-3099(22)00311-5","article-title":"Monoclonal antibody therapies against SARS-CoV-2","volume":"22","author":"Focosi","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1407149","article-title":"Research progress of spike protein mutation of SARS-CoV-2 mutant strain and antibody development","volume":"15","author":"Huan","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.20411\/pai.v10i1.752","article-title":"Escape of SARS-CoV-2 variants KP.1.1, LB.1, and KP3.3 from approved monoclonal antibodies","volume":"10","author":"Planas","year":"2024","journal-title":"Pathog. Immun."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0110","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.3390\/v16091419","article-title":"Elucidating the substrate envelope of enterovirus 68-3C protease: structural basis of specificity and potential resistance","volume":"16","author":"Azzolino","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0115","article-title":"A serological assay to detect SARS-CoV-2 seroconversion in humans","author":"Amanat","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0120","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/978-1-61779-379-0_18","article-title":"Ribosome display for the selection of Sac7d scaffolds","volume":"805","author":"Mouratou","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0125","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/bit.26463","article-title":"A novel, smaller scaffold for Affitins: showcase with binders specific for EpCAM","volume":"115","author":"Kalichuk","year":"2018","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0130","first-page":"274","article-title":"Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells","volume":"28","author":"Vallera","year":"2013","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003647","article-title":"A one pot, one step, precision cloning method with high throughput capability","volume":"3","author":"Engler","year":"2008","journal-title":"PLOS One"},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0140","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-1-4939-9853-1_2","article-title":"Affitins: ribosome display for selection of Aho7c-based affinity proteins","volume":"2070","author":"Kalichuk","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12896-019-0504-z","article-title":"Ex vivo evolution of human antibodies by CRISPR-X: from a naive B cell repertoire to affinity matured antibodies","volume":"19","author":"Devilder","year":"2019","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0150","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020106267","article-title":"Syncytia formation by SARS-CoV-2-infected cells","volume":"39","author":"Buchrieser","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0155","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41591-021-01318-5","article-title":"Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies","volume":"27","author":"Planas","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0160","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/sj.mt.6300135","article-title":"Lentiviral vectors encoding HIV-1 polyepitopes induce broad CTL responses in vivo","volume":"15","author":"Iglesias","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0165","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0170","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20220638","article-title":"Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2","volume":"219","author":"Planchais","year":"2022","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111845","article-title":"Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents","volume":"41","author":"Cao","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0180","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.celrep.2013.11.015","article-title":"Structural basis for enhanced HIV-1 neutralization by a dimeric immunoglobulin G form of the glycan-recognizing antibody 2G12","volume":"5","author":"Wu","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0185","first-page":"683","article-title":"Recombinant polymeric IgG: an approach to engineering more potent antibodies","volume":"12","author":"Smith","year":"1994","journal-title":"Biotechnology (N. Y)"},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0190","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1084\/jem.176.4.1191","article-title":"Engineered humanized dimeric forms of IgG are more effective antibodies","volume":"176","author":"Caron","year":"1992","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0195","doi-asserted-by":"crossref","first-page":"8728","DOI":"10.1038\/s41467-024-53033-7","article-title":"Lineage-specific pathogenicity, immune evasion, and virological features of SARS-CoV-2 BA.2.86\/JN.1 and EG.5.1\/HK.3","volume":"15","author":"Liu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0200","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41589-020-00679-1","article-title":"Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2","volume":"17","author":"Bracken","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0205","doi-asserted-by":"crossref","first-page":"e02438","DOI":"10.1128\/JVI.02438-20","article-title":"Potent neutralization of SARS-CoV-2 by hetero-bivalent alpaca nanobodies targeting the spike receptor-binding domain","volume":"95","author":"Ma","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0210","first-page":"e03562","article-title":"Novel affibody molecules specifically bind to SARS-CoV-2 spike protein and efficiently neutralize delta and omicron variants","volume":"11","author":"Du","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0215","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41587-022-01382-3","article-title":"The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants","volume":"40","author":"Rothenberger","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010799","article-title":"Biosynthetic proteins targeting the SARS-CoV-2 spike as anti-virals","volume":"18","author":"Th\u00e9bault","year":"2022","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0225","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1016\/j.ymthe.2023.08.010","article-title":"Inhalable Nanofitin demonstrates high neutralization of SARS-CoV-2 virus via direct application in respiratory tract","volume":"31","author":"Viollet","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ijbiomac.2025.149321_bb0230","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41579-022-00809-7","article-title":"SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies","volume":"21","author":"Cox","year":"2023","journal-title":"Nat. Rev. Microbiol."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025098782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025098782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:51:47Z","timestamp":1773845507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813025098782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":46,"alternative-id":["S0141813025098782"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.149321","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimized pipeline for generating highly potent neutralizing Affitins: Application to SARS-CoV-2 spike protein","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.149321","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"149321"}}